Retatrutide Cuts Sleep Apnea Events in Phase 3 Trials

Retatrutide reduced nighttime breathing interruptions in two phase 3 trials of adults with moderate-to-severe obstructive sleep apnea and overweight or obesity. After 80 weeks, people assigned to the investigational weekly injection had fewer interruptions than those assigned to placebo, including in a trial involving people with type 2 diabetes.

For someone waking up exhausted despite spending the night in bed, fewer interruptions are a concrete result. They are also a result with boundaries: retatrutide has not been approved by the U.S. Food and Drug Administration. An approved medication for some people with sleep apnea already exists, and these trials cannot tell us whether retatrutide works better than it.

What Changed in the Retatrutide Trials

Obstructive sleep apnea occurs when the upper airway repeatedly narrows or closes during sleep. Researchers track it with the apnea-hypopnea index, or AHI: the number of times breathing stops or becomes shallow per hour. That count gives a more direct measure of the condition than a bathroom scale or a report of how long someone slept.

The retatrutide trials tested three doses against placebo. TRIUMPH-1-OSA enrolled participants without type 2 diabetes; TRIUMPH-2-OSA enrolled participants with it. All had moderate-to-severe sleep apnea and a body mass index of at least 27. Participants received weekly injections, with sleep assessments at the start, week 24 and week 80.

All three doses improved breathing-interruption counts more than placebo after 80 weeks. At the higher doses, participants without diabetes had roughly 32 to 34 fewer interruptions per hour, compared with about 10 fewer in the placebo group. Among participants with diabetes, the corresponding reductions were roughly 25 and 10 per hour. Those are changes within each group from its starting point, rather than a count of how often people were still waking or struggling to breathe at the end.

Some participants crossed a threshold that could affect future treatment decisions. Among people taking higher doses, 39% to 52% reached no sleep apnea or mild sleep apnea without excessive daytime sleepiness, versus about 13% assigned to placebo. The thresholds are encouraging; a person’s CPAP prescription cannot be settled by a trial-wide percentage. The participants started with moderate-to-severe disease, and the result does not mean everyone taking the drug stopped needing airway support.

Retatrutide targets three hormone receptors, GLP-1, GIP and glucagon, and participants also lost weight. The trials measured breathing as well as weight, but they cannot separate how much of the breathing improvement came through weight loss from any other drug effect. They also do not establish that retatrutide prevents heart problems. Digestive symptoms were the most common side effects, and Eli Lilly, which is developing retatrutide, funded the trials.

The Medication that Arrived First

In December 2024, the FDA approved Zepbound, the brand name for tirzepatide, for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity. It was the first drug approved for this use. The wording matters for a reader weighing options today: sleep apnea also occurs in people who do not have obesity, and an approval for a defined group does not extend to every person with the condition.

The FDA based that decision on two placebo-controlled studies involving 469 adults without type 2 diabetes. One study enrolled people using positive airway pressure, or PAP; the other enrolled people unable or unwilling to use it. After 52 weeks, tirzepatide reduced AHI more than placebo, and a greater proportion of participants reached remission or mild sleep apnea with resolution of symptoms. The agency said the breathing improvement was likely related to reduced body weight.

This history changes how to read the retatrutide result. Medication that reduces body weight had already become an approved sleep-apnea option for a defined population. Retatrutide may eventually add another option, with its diabetes trial offering information about a group absent from the studies the FDA described for tirzepatide’s sleep-apnea approval. That difference in study populations is useful context, though it cannot predict what indication retatrutide might receive if regulators review it.

The two drugs also cannot be ranked by placing their trial headlines side by side. Retatrutide’s studies ran for 80 weeks and included a separate group with type 2 diabetes; the tirzepatide studies described by the FDA ran for 52 weeks and enrolled people without it. Each drug was tested against its own placebo group, under its own study conditions. A larger-looking change in one set of figures would not establish that drug as the better sleep-apnea treatment. No participant in these studies was randomized between retatrutide and tirzepatide.

That leaves a reasonable question for future research: among patients eligible for either approach, which treatment improves breathing, symptoms and tolerability most? It is a question the current comparison cannot answer.

Breathing, Access and the Decisions People Face Now

A CPAP machine keeps an airway open during sleep. It remains a standard treatment for moderate-to-severe sleep apnea, although some people find the mask uncomfortable and struggle to wear it nightly. That experience deserves a conversation about workable treatment, rather than a lecture about willpower. Even substantial weight loss may leave someone needing airway support.

The practical questions extend beyond an AHI score. A person may need an assessment, a treatment they can tolerate and a way to pay for continuing care. FDA approval defines where a drug can be marketed for a condition; it does not, by itself, settle an individual’s insurance coverage, costs or whether that medicine is suitable for them. Nor does an investigational drug offer a treatment someone can simply request at a pharmacy. Those constraints can decide whether a promising result ever becomes relief on an ordinary Tuesday morning.

For someone already using CPAP, the retatrutide findings are no reason to stop a prescribed treatment. A clinician can discuss persistent daytime exhaustion, difficulties using PAP and options appropriate to the person’s health and access. Zepbound has an approved sleep-apnea indication for some adults, but it also has side effects and contraindications, including restrictions for people with certain thyroid-cancer histories. Treatment choices require an individual assessment, rather than a contest between two trial headlines.

Retatrutide has supplied a promising answer to one question: in the people studied, breathing interruptions fell more than with placebo. The next answers concern regulatory review, longer-term safety and whether another treatment can reach the people whose nights, and mornings, need it.